Vorinostat, an FDA-approved HDACi, was effective in overcoming BIM deletion polymorphism-induced TKI resistance in non-small-cell lung cancer (NSCLC) when combined with an EGFR TKI [9]. Here, BCL2L11 is linked to non-small cell lung carcinoma.